Intellia Therapeutics, Inc. (NTLA)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
11.42 USD
+0.08
(0.705%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 11.38 -0.04 (-0.040%) ⇩ (Oct. 16, 2026, 4:32 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:11 a.m. EDT
The immediate outlook is driven entirely by the pending Phase 3 clinical trial results, creating a classic 'binary event' setup. While the recent price action shows some resilience, the underlying business fundamentals are deteriorating sharply; revenue has contracted by nearly half year-over-year, and the company is burning significant cash with negative operating margins. The balance sheet remains intact due to prior capital raises, but the path to profitability is obscured. Analysts see a massive upside potential (mean target ~$23), yet the lack of recent earnings growth and the heavy short interest suggest the market is pricing in a high-risk scenario where the drug fails or underperforms. The options market reflects this tension perfectly: traders are buying deep out-of-the-money calls for a moonshot gain while hedging with tight put protection, indicating they expect a volatile gap rather than a smooth recovery. Until the clinical data arrives, the investment case is speculative at best. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.083925 |
| AutoTheta | 0.086514 |
| AutoETS | 0.086657 |
| AutoARIMA | 0.086657 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 3.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.344 |
| Excess Kurtosis | -0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.088 |
| Revenue per Share | 0.498 |
| Market Cap | 1,600,246,784 |
| Forward P/E | -4.45 |
| Beta | 1.80 |
| Website | https://www.intelliatx.com |
As of Oct. 10, 2026, 4:11 a.m. EDT: Speculators are positioning aggressively for volatility rather than a specific directional outcome. Call Open Interest is heavily skewed toward out-of-the-money strikes (35.0 and 42.0 for 2028 expiry), while Put Open Interest clusters tightly around the current price (10.0–13.0 range). This distribution suggests traders are betting on a binary event—likely the upcoming Phase 3 readout—where the stock could gap up significantly or crash, rather than expecting a steady grind higher. The massive IV spikes at deep strikes confirm this binary expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.54181814 |
| Address1 | 40 Erie Street |
| Address2 | Suite 130 |
| All Time High | 202.73 |
| All Time Low | 5.9 |
| Ask | 13.92 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 6,935,730 |
| Average Daily Volume3 Month | 4,282,878 |
| Average Volume | 4,282,878 |
| Average Volume10Days | 6,935,730 |
| Beta | 1.801 |
| Bid | 8.2 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.197 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.42 |
| Current Ratio | 6.648 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.675 |
| Day Low | 10.91 |
| Debt To Equity | 10.088 |
| Display Name | Intellia Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -414,400,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.955 |
| Enterprise To Revenue | 20.581 |
| Enterprise Value | 1,224,687,744 |
| Eps Current Year | -3.1441 |
| Eps Forward | -2.56462 |
| Eps Trailing Twelve Months | -3.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.2535 |
| Fifty Day Average Change | -0.8334999 |
| Fifty Day Average Change Percent | -0.06802137 |
| Fifty Two Week Change Percent | -54.181816 |
| Fifty Two Week High | 28.25 |
| Fifty Two Week High Change | -16.83 |
| Fifty Two Week High Change Percent | -0.59575224 |
| Fifty Two Week Low | 7.95 |
| Fifty Two Week Low Change | 3.4700003 |
| Fifty Two Week Low Change Percent | 0.43647802 |
| Fifty Two Week Range | 7.95 - 28.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,462,541,400,000 |
| Float Shares | 134,213,347 |
| Forward Eps | -2.56462 |
| Forward P E | -4.4529014 |
| Free Cashflow | -249,825,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 377 |
| Fullday Change | 0.03999996 |
| Fullday Change Percent | 0.35273334 |
| Fullday Price | 11.38 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -222,816,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03838 |
| Held Percent Institutions | 1.0008 |
| Implied Shares Outstanding | 140,126,693 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Intellia Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,600,246,784 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_277799796 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -399,975,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,731,965,925 |
| Number Of Analyst Opinions | 18 |
| Open | 11.6 |
| Operating Cashflow | -346,643,008 |
| Operating Margins | -14.72255 |
| Overall Risk | 8 |
| Phone | 857 285 6200 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -0.35026237 |
| Post Market Price | 11.38 |
| Post Market Time | 1,792,182,730 |
| Previous Close | 11.34 |
| Price Eps Current Year | -3.6322 |
| Price Hint | 2 |
| Price To Book | 2.1974216 |
| Price To Sales Trailing12 Months | 26.892193 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.606 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.35 |
| Region | US |
| Regular Market Change | 0.07999992 |
| Regular Market Change Percent | 0.7054667 |
| Regular Market Day High | 11.675 |
| Regular Market Day Low | 10.91 |
| Regular Market Day Range | 10.91 - 11.675 |
| Regular Market Open | 11.6 |
| Regular Market Previous Close | 11.34 |
| Regular Market Price | 11.42 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 8,219,716 |
| Return On Assets | -0.30144 |
| Return On Equity | -0.55438 |
| Revenue Growth | -0.462 |
| Revenue Per Share | 0.498 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 140,126,693 |
| Shares Percent Shares Out | 0.32189998 |
| Shares Short | 45,110,513 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 43,928,014 |
| Short Name | Intellia Therapeutics, Inc. |
| Short Percent Of Float | 0.4055 |
| Short Ratio | 11.08 |
| Source Interval | 15 |
| State | MA |
| Symbol | NTLA |
| Target High Price | 61.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 23.11111 |
| Target Median Price | 16.0 |
| Total Cash | 437,759,008 |
| Total Cash Per Share | 3.124 |
| Total Debt | 73,410,000 |
| Total Revenue | 59,506,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.986125 |
| Two Hundred Day Average Change | -1.5661249 |
| Two Hundred Day Average Change Percent | -0.120599866 |
| Type Disp | Equity |
| Volume | 8,219,716 |
| Website | https://www.intelliatx.com |
| Zip | 2,139 |